Efficacy of rilmenidine, a selective I1 imidazoline receptor binding agent in diabetic hypertensive patients.
Hypertension is a frequent complication in diabetes, and microalbuminuria has become an essential index of cardiovascular prognosis in type 2 diabetics. The pilot study reported here shows that rilmenidine, in addition to its antihypertensive action and good clinical tolerability, has the further advantage of reducing microalbuminuria, similar to captopril.
Dupuy
O
O
Hôpital Bégin, St. Mandé, France.
Bauduceau
B
B
Mayaudon
H
H
D000959:Antihypertensive Agents / Q000378:metabolism* / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003925:Diabetic Angiopathies / Q000188:drug therapy*; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D054755:Imidazoline Receptors; D010080:Oxazoles / Q000378:metabolism* / Q000627:therapeutic use*; D011955:Receptors, Drug / Q000378:metabolism*; D000077769:Rilmenidine
D000959:Antihypertensive Agents; D054755:Imidazoline Receptors; D010080:Oxazoles; D011955:Receptors, Drug; C410887:imidazoline I1 receptors; D000077769:Rilmenidine